Insys Therapeutics, Inc. (INSY)
(Delayed Data from NSDQ)
$4.19 USD
+0.04 (0.96%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.19 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.19 USD
+0.04 (0.96%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.19 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
IDEXX Laboratories (IDXX) Q2 Earnings & Revenues Top, View Up
by Zacks Equity Research
IDEXX Laboratories (IDXX) rides high on strength across all segments in Q2 with significant contributions from the Companion Animal Group business. Moreover, a raised guidance buoys optimism.
Hill-Rom Holdings (HRC) Beats Q3 Earnings, Misses Revenues
by Zacks Equity Research
Hill-Rom Holdings (HRC) rides high on international growth and product innovation.
NuVasive (NUVA) Beats on Q2 Earnings, Retains 2017 View
by Zacks Equity Research
NuVasive (NUVA) rides high on continued growth in international business in Q2. Also, the company has worked on revamping its organizational structure.
Omnicell (OMCL) Earnings Meet, Revenues Beat Estimates in Q2
by Zacks Equity Research
Omnicell (OMCL) benefited from high XT revenues and strength in IV Solutions in Q2.
LeMaitre Vascular (LMAT) Worth a Look: Stock Jumps 19.5%
by Zacks Equity Research
LeMaitre Vascular, Inc. (LMAT) shares jumped above 19% in the last trading session.
Abaxis (ABAX) Misses Earnings & Revenue Estimates in Q1
by Zacks Equity Research
Despite Abaxis' lackluster performance in the fiscal first quarter, its new marketing strategies and recent launches buoy optimism.
GNC Holdings (GNC) Tops Q2 Earnings, Misses Sales Estimates
by Zacks Equity Research
Sluggish performance by the U.S. & Canada international and manufacturing/wholesale segments marred second-quarter results for GNC Holdings (GNC).
Align Technology (ALGN) Beats on Q2 Earnings and Revenues
by Zacks Equity Research
Align Technology (ALGN) rides high in Q2 banking on robust growth in the Invisalign space.
QIAGEN (QGEN) Beats on Earnings & Sales in Q2, Raises View
by Zacks Equity Research
QIAGEN (QGEN) continues to bank on the Molecular Diagnostics space for growth.
McKesson (MCK) Misses Earnings Estimates in Q1, Raises View
by Zacks Equity Research
McKesson's (MCK) performance was muted in the first quarter owing to branded to generic conversions and competition in its pharmacy business.
Integra LifeSciences (IART) Q2 Earnings Meet, Revenues Miss
by Zacks Equity Research
Integra LifeSciences' (IART) solid performance in the Orthopedics and Tissue Technologies was the key highlight of the second quarter.
CONMED (CNMD) Earnings Meet, Revenues Beat Estimates in Q2
by Zacks Equity Research
CONMED's (CNMD) strong global performance was a key highlight in the second quarter of 2017.
LabCorp (LH) Beats on Q2 Earnings and Sales, Guidance Up
by Zacks Equity Research
LabCorp's (LH) dull Covance Drug Development performance is offset by solid growth in Diagnostics. Increased guidance raises hope.
Chemed (CHE) Q2 Earnings & Revenues Rise Y/Y, View Revised
by Zacks Equity Research
Chemed (CHE) rides high on Roto-Rooter in second-quarter 2017. An encouraging bottom-line projection raises hopes.
Express Scripts (ESRX) Earnings Top in Q2, FY17 View Up
by Zacks Equity Research
Express Scripts (ESRX) perform well in the second quarter on the back of operational cost improvement backed by focus on home delivery and specialty services.
PetMed Express (PETS) Tops Earnings, Revenue Estimates in Q1
by Zacks Equity Research
PetMed (PETS) initiated fiscal 2018 with better-than-expected results in the first quarter, beating both earnings and revenues.
Abbott Labs (ABT) Beats on Q2 Earnings and Sales, View Up
by Zacks Equity Research
Abbott Labs' (ABT) Q2 performance was strong on solid EPD and Medical Device growth. The stock's guidance for 2017 has also been raised.
Quest Diagnostics Closes Deal to Acquire 2 Labs in Texas
by Zacks Equity Research
Quest Diagnostics (DGX) acquires Med Fusion and Clear Point lab businesses to grow in oncology space.
Align Technology Hits a 52-Week High on Solid Prospects
by Zacks Equity Research
Share price of San Jose, CA-based Align Technology, Inc. (ALGN) reached a new 52-week high of $157.86 on Jul 17, eventually closing a bit lower at $156.21.
Medtronic InterStim System Shows Five-Year Positive Results
by Zacks Equity Research
Medtronic plc (MDT) has announced that its InterStim system provides sustained long-term efficacy and improved quality of life for overactive bladder (OAB) patients at the end of five years.
Company News for July 17, 2017
by Zacks Equity Research
Companies In the News are: CYBR,ARNC,T,INSY,TWX
Hill-Rom (HRC) at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Batesville, IN-based Hill-Rom Holdings, Inc. (HRC) scaled a new 52-week high of $84.17 on Jul 14.
MedTech Industry Outlook - July 2017
by Zacks Equity Research
The overall expectation is that President Trump's legislative change for MedTech will result in lower taxes and regulation for the industry as a whole.
Play the Marijuana Rush as First Marijuana-Focused ETF Launches
by Arpita Dutt
The medical marijuana industry has been gaining a lot of importance and attracting interest from investors over the last few quarters with companies like GW Pharma (GWPH) making headlines.
Zacks Industry Outlook Highlights: Varian Medical Systems, T2 Biosystems, Edwards Lifesciences, INSYS Therapeutics and Cerner
by Zacks Equity Research
Zacks Industry Outlook Highlights: Varian Medical Systems, T2 Biosystems, Edwards Lifesciences, INSYS Therapeutics and Cerner